# US 2021/0332069 A1 · Borate-Based Drug And Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332069 A1
- Document ID: US20210332069A1
- Status: Published application
- Kind: A1
- Application number: 17/273,964
- Filed: 2019-09-05
- Published: 2021-10-28
- Earliest claimed: 2018-09-14
- Assignees: Chengdu Origin Biotechnology Limited Company
- Applicants: Chengdu Origin Biotechnology Limited Company
- Inventors: Peng He; Haiyan Li; Hai Zhao; Pei Huang; Xuechao Wang
- Web page: https://patentgrep.com/patent/US20210332069A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07F 5/025: {Boronic and borinic acid compounds}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/02: specific for leukemia
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present application provides a borate ester compound suitable for being used as a proteasome inhibitor, a preparation method and use thereof, and the compound has the following structure wherein, R1, R2 is asymmetric substituent in para-position, and R1 and R2 are both selected from the group consisting of halogen; and when R1 is F, R2 is not Cl; when R1 is Cl, R2 is not Br or F; and when R1 is Br, R2 is not Cl; X1, X2 is selected from the group consisting of hydroxyl, or X1 and X2 together form a substituted or unsubstituted 4 to 10 membered ring containing 1 to 4 heteroatoms being selected from the group consisting of O, N and S.

## Claims

### Claim at position 1

1-6. (canceled)

### Claim 7

A compound of formula (I′) or stereoisomers, enantiomers, tautomers or mixture thereof, or pharmaceutically acceptable salts, solvates, prodrugs or boric anhydride thereof
when R1 is F, R2 is Br; when R1 is Br, R2 is F;
X1 and X2 are OH; or
X1 and X2 together with the boron atom to which they are connected form a ring structure, and the ring structure is
wherein,
R3, R4, R5, R6, R7, R8 and R9 are each independently hydrogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 3 to 7 membered heterocycloalkyl, phenyl, benzyl, 5 to 10 membered heteroaryl, COOH, C1-C6 alkyl-COOH, OH or halogen, wherein the C1-C6 alkyl, the C1-C6 alkenyl, the C1-C6 alkynyl, the C1-C6 alkoxy, the C3-C8 cycloalkyl, the 3 to 7 membered heterocycloalkyl, the phenyl, the benzyl, the 5 to 10 membered heteroaryl and the C1-C6 alkyl-COOH are optionally substituted with groups being selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, amino, cyano, acyl, carboxyl, C1-C6 alkyl-COOH, hydroxy, C1-C6 alkoxy, C1-C6 haloalkoxy, carbonyl, 3 to 7 membered heterocycloalkyl, C5-C10 aryl and 5 to 10 membered heteroaryl.

### Claim 8 (depends on 7)

The compound or stereoisomers, enantiomers, tautomers or mixture thereof, or pharmaceutically acceptable salts, solvates, prodrugs or boric anhydride thereof of claim 7, wherein when R1 is F, R2 is Br.

### Claim 9 (depends on 7)

The compound or stereoisomers, enantiomers, tautomers or mixture thereof, or pharmaceutically acceptable salts, solvates, prodrugs or boric anhydride thereof of claim 7, wherein the ring structure is
wherein R3 and R4 are each independently hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 3 to 7 membered heterocycloalkyl, phenyl, benzyl, 5 to 10 membered heteroaryl, COOH or C1-C6 alkyl-COOH, and the C1-C6 alkyl, the C1-C6 alkoxy, the C3-C8 cycloalkyl, the 3 to 7 membered heterocycloalkyl, the phenyl, the benzyl, the 5 to 10 membered heteroaryl, and the C1-C6 alkyl-COOH are optionally substituted by groups being selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, amino, cyano, acyl, carboxyl, C1-C6 alkyl-COOH, hydroxy, C1-C6 alkoxy, C1-C6 haloalkoxy, carbonyl, 3 to 7 membered heterocycloalkyl, C5-C10 aryl and 5 to 10 membered heteroaryl.

### Claim 10 (depends on 7)

The compound or stereoisomers, enantiomers, tautomers or mixture thereof, or pharmaceutically acceptable salts, solvates, prodrugs or boric anhydride thereof of claim 7,
wherein the ring structure is
wherein
R5 and R6 are each independently hydrogen, C1-C6 alkyl or C1-C6 alkoxy;
R7 and R8 are each independently hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 3 to 7 membered heterocycloalkyl, phenyl, benzyl, 5 to 10 membered heteroaryl, COOH or C1-C6 alkyl-COOH;
the C1-C6 alkyl, the C1-C6 alkoxy, the C3-C8 cycloalkyl, the 3 to 7 membered heterocycloalkyl, the phenyl, the benzyl, the 5 to 10 membered heteroaryl, and the C1-C6 alkyl-COOH are optionally substituted by groups being selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, amino, cyano, acyl, carboxyl, C1-C6 alkyl-COOH, hydroxy, C1-C6 alkoxy, C1-C6 haloalkoxy, carbonyl, 3 to 7 membered heterocycloalkyl, C5-C10 aryl and 5 to 10 membered heteroaryl.

### Claim 11 (depends on 10)

The compound or stereoisomers, enantiomers, tautomers or mixture thereof, or pharmaceutically acceptable salts, solvates, prodrugs or boric anhydride thereof of claim 10, wherein R5 and R6 are H, R7 and R8 are each independently hydrogen, C1-C6 alkyl, C1-C6 alkoxy, COOH or C1-C6 alkyl-COOH, and the C1-C6 alkyl, the C1-C6 alkoxy and the C1-C6 alkyl-COOH are optionally substituted by groups being selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, amino, cyano, acyl, carboxyl, C1-C6 alkyl-COOH, hydroxy, C1-C6 alkoxy, C1-C6 haloalkoxy, carbonyl, 3 to 7 membered heterocycloalkyl, C5-C10 aryl and 5 to 10 membered heteroaryl.

### Claim 12 (depends on 7)

The compound or stereoisomers, enantiomers, tautomers or mixture thereof, or pharmaceutically acceptable salts, solvates, prodrugs or boric anhydride thereof of claim 7, the ring structure is
wherein, R9 is hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, COOH or C1-C6 alkyl-COOH, and the C1-C6 alkyl, the C1-C6 alkoxy, the C3-C5 cycloalkyl and the C1-C6 alkyl-COOH are optionally substituted by groups being selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, amino, cyano, acyl, carboxyl, C1-C6 alkyl-COOH, hydroxy, C1-C6 alkoxy, C1-C6 haloalkoxy and carbonyl.

### Claim 13 (depends on 7)

The compound or stereoisomers, enantiomers, tautomers or mixture thereof, or pharmaceutically acceptable salts, solvates, prodrugs or boric anhydride thereof of claim 7, wherein
the ring structure is
wherein R3 and R4 are each independently hydrogen, C1-C6 alkyl, phenyl, benzyl, COOH or C1-C6 alkyl-COOH; preferably, R3 and R4 are each independently hydrogen, phenyl, COOH or C1-3 alkyl-COOH; or
the ring structure is
wherein R5 and R6 are each independently hydrogen or C1-C6 alkyl; and R7 and R8 are each independently H, COOH or C1-C6 alkyl-COOH; preferably, both R5 and R6 are H, and R7 and R8 are each independently COOH or C1-3 alkyl-COOH; or
the ring structure is
wherein R9 is hydrogen, C1-C6 alkyl, COOH or C1-C6 alkyl-COOH; preferably, R9 is hydrogen, C1-C3 alkyl, COOH or C1-C3 alkyl-COOH.

### Claim 14 (depends on 8)

The compound or stereoisomers, enantiomers, tautomers or mixture thereof, or pharmaceutically acceptable salts, solvates, prodrugs or boric anhydride thereof of claim 8, wherein
the ring structure is
R4 wherein R3 and R4 are each independently hydrogen, phenyl, COOH or CH2—COOH; or
the ring structure is
wherein R5 and R6 are hydrogen; R7 and R8 are independently COOH or CH2—COOH; or
the ring structure is
wherein R9 is hydrogen.

### Claim 15 (depends on 7)

The compound or stereoisomers, enantiomers, tautomers or mixture thereof, or pharmaceutically acceptable salts, solvates, prodrugs or boric anhydride thereof of claim 7, wherein when R1 is F, R2 is Br,
the ring structure is
wherein R3 and R4 are each independently hydrogen, phenyl, COOH or CH2—COOH; or
the ring structure is
wherein R5 and R6 are hydrogen; R7 and R8 are independently hydrogen, COOH or CH2—COOH; or
the ring structure is
wherein R9 is hydrogen.

### Claim 16 (depends on 7)

The compound or stereoisomers, enantiomers, tautomers or mixture thereof, or pharmaceutically acceptable salts, solvates, prodrugs or boric anhydride thereof of claim 7, wherein the compound is:

### Claim 17 (depends on 7)

The compound or stereoisomers, enantiomers, tautomers or mixture thereof, or pharmaceutically acceptable salts, solvates, prodrugs or boric anhydride thereof of claim 7, wherein the compound is:

### Claim 18 (depends on 7)

A pharmaceutical preparation, comprising the compound or stereoisomers, enantiomer or tautomers or mixtures thereof, or pharmaceutically acceptable salts, solvates or prodrugs thereof of claim 7, and a pharmaceutically acceptable excipient.

### Claim 19 (depends on 7)

A pharmaceutical composition, comprising the compound or stereoisomers, enantiomer or tautomers or mixtures thereof, or pharmaceutically acceptable salts, solvates or prodrugs thereof of claim 7, and one or more other drugs for preventing or treating tumors.

### Claim 20 (depends on 7)

A method for preventing and/or treating tumors; comprising administering the compound or stereoisomers, enantiomer or tautomers or mixtures thereof, or pharmaceutically acceptable salts, solvates or prodrugs thereof of claim 7 to a subject in need thereof,
wherein the tumors preferably are selected from plasmacytoma, mantle cell tumor, multiple myeloma, melanoma, breast cancer, liver cancer, cervical cancer, lung cancer, lymphoma, leukemia, ovarian cancer, renal cancer, gastric cancer, nasopharyngeal cancer, thyroid cancer, pancreatic cancer, prostate cancer, adenocarcinoma, mouth cancer, esophageal cancer, squamous cell cancer and colon cancer.

### Claim 21

(canceled)

### Claim 22 (depends on 7)

A method for inhibiting proteasome, comprising administering the compound or stereoisomers, enantiomer or tautomers or mixtures thereof, or pharmaceutically acceptable salts, solvates or prodrugs thereof of claim 7 to a subject in need thereof.
